摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

S-methyl N,N-diisopropylthiocarbamate | 57124-37-5

中文名称
——
中文别名
——
英文名称
S-methyl N,N-diisopropylthiocarbamate
英文别名
Carbamothioic acid, bis(1-methylethyl)-, S-methyl ester;S-methyl N,N-di(propan-2-yl)carbamothioate
S-methyl N,N-diisopropylthiocarbamate化学式
CAS
57124-37-5
化学式
C8H17NOS
mdl
——
分子量
175.295
InChiKey
ZGUSHQXAXGSJCD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    92-96.5 °C(Press: 14 Torr)
  • 密度:
    0.975±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    45.6
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:cbcb25d48b0f5801baebe81157ba32ce
查看

反应信息

  • 作为反应物:
    描述:
    S-methyl N,N-diisopropylthiocarbamate三丁基氯化锡四甲基乙二胺仲丁基锂 作用下, 以 乙醚 为溶剂, 以94%的产率得到S-((tributylstannyl)methyl) diisopropylcarbamothioate
    参考文献:
    名称:
    99%ee的手性α-氧-[2H1]甲基锂的制备及其构型稳定性的测定
    摘要:
    (三丁基锡烷基)甲基 2,2,6,6-四甲基哌啶-1-羧酸盐在 -78 摄氏度下用 t-BuLi/TMEDA 金属化,并用衍生自 (R,R)-1,2-二环己基乙烷的混合硼酸盐进行硼酸化1,2-二醇和叔丁醇得到等量的非对映体硼酸酯 31/32。硼酸盐 31 和 32 用 LiBEt3D 还原,然后用碱性 H2O2 氧化,分别得到 99% ee 的 (S)- 和 (R)-三丁基甲锡烷基-[1-2H1] 甲醇。在 -78 和 0 摄氏度下用 n-BuLi 处理它们各自的磷酸盐得到微观构型稳定的膦酰氧基取代的 [2H1] 甲基锂,其重排为 ee > 98% 的羟基-[1-2H1]甲基膦酸盐(磷酸盐-膦酸盐重排) . 然后,对映体三丁基甲锡烷基-[1-2H1] 甲醇的 N-二异丙基氨基甲酸酯被金属转移,得到氨基甲酰氧基取代的手性 [2H1] 甲基锂,在 - 78 摄氏度,由苯甲醛诱捕实验推断。这些甲基锂的化学稳定性在
    DOI:
    10.1021/ja066183s
  • 作为产物:
    描述:
    二异丙胺 在 sulfur 作用下, 以 四氢呋喃 为溶剂, 20.0 ℃ 、101.33 kPa 条件下, 反应 20.0h, 生成 S-methyl N,N-diisopropylthiocarbamate
    参考文献:
    名称:
    容易小号-烷基硫代氨基甲酸盐通过与一氧化碳和硫胺的新颖DBU辅助羰基合成
    摘要:
    已经开发了一种新颖的DBU辅助的胺与一氧化碳和硫的羰基化反应,以合成硫代氨基甲酸酯的S-烷基。在DBU(1,8-二氮杂双环[5.4.0]十一碳-7-烯)的存在下,š -烷基硫代氨基甲酸盐在选自胺,一氧化碳,硫,和烷基卤化物在温和条件下高收率合成(1个大气压, 20°C)。然而,在不存在DBU的情况下,未观察到S-烷基硫代氨基甲酸酯的形成。本DBU辅助的羰基化反应还可用于苯硫威和邻苯甲酸(除草剂)和氨基甲酰氯的新合成方法。
    DOI:
    10.1016/s0040-4020(03)00031-0
点击查看最新优质反应信息

文献信息

  • Solvent-assisted thiocarboxylation of amines and alcohols with carbon monoxide and sulfur under mild conditions
    作者:Takumi Mizuno、Toshiyuki Iwai、Yoshio Ishino
    DOI:10.1016/j.tet.2005.06.114
    日期:2005.9
    DMSO or DMF as a solvent strongly accelerated the thiocarboxylation of amines and alcohols with carbon monoxide and sulfur. Under mild conditions (1 atm, 20 degrees C), this thiocarboxylation of amines assisted by DMSO with carbon monoxide and sulfur has been developed into a practical and convenient synthetic method for S-alkyl thiocarbamates in good to excellent yields, including EPTC, thiobencarb, orbercarb, and molinate (herbicides). DMF also showed the similar solvent effect. NMP slightly decreased the effect for the thiocarboxylation of amines, and the yield of S-alkyl thiocarbamate was lowered in DMAc. Surprisingly, no formation of S-alkyl thiocarbamate was observed at the use of the other solvents, such as THF, hexane, toluene, AcOEt, MeCN, MeOH, and H2O. The present solvent-assisted thiocarboxylation with carbon monoxide and sulfur could be also applied to a new synthesis of S-alkyl O-alkyl carbonothioates from alcohols under mild conditions (1 atm, 20 degrees C) in DMF using DBU (1,8-diazabicyclo[5.4.0]undec-7-ene). (c) 2005 Elsevier Ltd. All rights reserved.
  • Novel N-substituted 2-oxo-3-benzothiazoline derivatives, their use as leguminous plant growth regulants, and plant growth regulating compositions containing said derivatives as the active ingredients
    申请人:MONSANTO COMPANY
    公开号:EP0007161B1
    公开(公告)日:1981-10-21
  • ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN ROR1 AND USE FOR THE SAME
    申请人:Park Yun Hee
    公开号:US20210069342A1
    公开(公告)日:2021-03-11
    The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
查看更多